A Prospective Study of Surgical Treatment Strategies for Chordoma

Not Applicable

Recruiting

• Conditions: Chordoma of Spine; Surgery

• Registration Number: NCT05707767
• Lead Sponsor: Xuanwu Hospital, Beijing

Brief Summary

Chordoma is a rare but locally invasive cancer that arises from the embryonic notochord. Total resection is challenging in mobile spine because of the complex anatomy and bone invasion.

Detailed Description

Not available

Study Timeline

• Status Verified: 2022-10
• Study First Submitted: 2022-10-09
• Study First Submitted QC: 2023-01-27
• Study Start: 2023-02-01
• Study First Posted: 2023-02-01
• Last Update Submitted: 2023-07-17
• Last Update Posted: 2023-07-19
• Primary Completion: 2024-09-30
• Study Completion: 2024-09-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• Between the ages of 18 and 70 ys,
• With a diagnosis of chordoma confirmed by pathology,
• Undergone surgical treatment in our hospital,
• Available for clinical follow-up and agree to long-term clinical follow-up and sign informed consent.

Exclusion Criteria

• Suffer from other tumors,
• Suffer from cardiovascular disease, cerebrovascular disease, or immune system disease.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Excision Extension	1 week after surgery.	Clinical and radiographic assessments of excision extension of tumor.

Secondary Outcome Measures

Name	Time	Method
ORR (Objective Response Rate)	2 years	Objective Response Rate of patient underwent surgery.
DFS (Disease Free Survival)	2 years	Disease Free Survival of patient underwent surgery.
PFS (Progression-Free Survival)	2 years	Progression-Free Survival of patient underwent surgery.
OS (Overall Survival)	2 years	Overall Survival of patient underwent surgery.

Trial Locations

Locations (1)

Xuanwu Hospital, Capital Medical University; 🇨🇳 Beijing, China